CARA THERAPEUTICS, INC. (NASDAQ:CARA) Files An 8-K Other Events
Item8.01. Other Events.
On March28, 2017, Cara Therapeutics, Inc. issued a press release
announcing results from Part A of its two-part Phase 2/3 adaptive
design trial of its product candidate, I.V. CR845, in dialysis
patients suffering from moderate-to-severe uremic pruritus. A
copy of this press release is attached as Exhibit 99.1 hereto and
incorporated herein by reference.
Item9.01. Financial Statements and Exhibits.
| (d) | Exhibits |
|
ExhibitNo. |
Description |
|
| 99.1 | Press Release dated March28, 2017. |
About CARA THERAPEUTICS, INC. (NASDAQ:CARA)
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body’s peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845, and CR701. The Company’s I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. The Company is developing an oral version of CR845 for the treatment of moderate-to-severe acute and chronic pain. The Company’s CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with cannabinoid receptor subtypes, with no off-target activities. CR701 is in preclinical-stage of development. CARA THERAPEUTICS, INC. (NASDAQ:CARA) Recent Trading Information
CARA THERAPEUTICS, INC. (NASDAQ:CARA) closed its last trading session up +1.10 at 19.25 with 2,479,906 shares trading hands.